As of 2025-07-03, the Intrinsic Value of Inozyme Pharma Inc (INZY) is -8.26 USD. This INZY valuation is based on the model Peter Lynch Fair Value. With the current market price of 4.00 USD, the upside of Inozyme Pharma Inc is -306.62%.
Based on its market price of 4.00 USD and our intrinsic valuation, Inozyme Pharma Inc (INZY) is overvalued by 306.62%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
Range | Selected | Upside | |
a | |||
Fair Value | -8.26 - -8.26 | -8.26 | -306.62% |
P/E | (16.56) - (30.08) | (21.57) | -639.3% |
DDM - Stable | (11.87) - (41.46) | (26.67) | -766.6% |
DDM - Multi | (9.80) - (27.84) | (14.64) | -466.0% |
Market Cap (mil) | 258.24 |
Beta | 5.56 |
Outstanding shares (mil) | 64.56 |
Enterprise Value (mil) | 278.68 |
Market risk premium | 4.60% |
Cost of Equity | 10.67% |
Cost of Debt | 5.00% |
WACC | 9.61% |